NANOG Antibody is affinity chromatography purified via peptide column.
免疫原
NANOG antibody was raised against a 19 amino acid synthetic peptide near the center of human NANOG. The immunogen is located within amino acids 130 - 180 of NANOG.
NANOG antibody can be used for detection of NANOG by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
限制
仅限研究用
状态
Liquid
浓度
1 mg/mL
缓冲液
NANOG Antibody is supplied in PBS containing 0.02 % sodium azide.
储存液
Sodium azide
注意事项
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
-20 °C,4 °C
储存方法
NANOG antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
抗原
Nanog (NANOG)
(Nanog Homeobox (NANOG))
别名
NANOG
背景
NANOG Antibody: Expression of NANOG is required for the maintenance of pluripotency in epiblast and embryonic stem (ES) cells as well as for the ability to maintain ES self-renewal independently of LIF/Stat3. The role of NANOG in embryonic development suggested that it might be useful in the creation of stem cells that might be useful in cell replacement therapies in the treatment of several degenerative diseases. Artificial stem cells, termed induced pluripotent stem (iPS) cells, can be created by expressing POU5F1 (also known as Oct-4), another germline-specific transcription factor, and the transcription factors Sox2, Klf4 and Lin28 along with c-Myc in mouse fibroblasts. More recently, experiments have demonstrated that iPS cells could be generated using expression plasmids expressing NANOG, Sox2, KlfF4 and c-Myc, eliminating the need for virus introduction, thereby addressing a safety concern for potential use of iPS cells in regenerative medicine.